CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Meeting Abstract
| Authors: | Yau, T.; Park, J. W.; Finn, R. S.; Cheng, A. L.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K. H.; Harding, J. J.; Merle, P.; Rosmorduc, O.; Wyrwicz, L.; Schott, E.; Choo, S. P.; Kelley, R. K.; Begic, D.; Chen, G.; Neely, J.; Anderson, J.; Sangro, B. |
| Abstract Title: | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.029 |
| Language: | English |
| ACCESSION: | WOS:000491295500162 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.029 |
| Notes: | Meeting Abstract: LBA38_PR -- Appears on pages v874-v875 of the abstract book -- Source: Wos |
